171 related articles for article (PubMed ID: 38293718)
21. No association of NAFLD-related polymorphisms in PNPLA3 and TM6SF2 with all-cause and cardiovascular mortality in an Austrian population study.
Semmler G; Balcar L; Wernly S; Datz L; Semmler M; Rosenstatter L; Stickel F; Aigner E; Wernly B; Datz C
Wien Klin Wochenschr; 2024 May; 136(9-10):251-257. PubMed ID: 37103556
[TBL] [Abstract][Full Text] [Related]
22. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
[TBL] [Abstract][Full Text] [Related]
23.
Meroni M; Dongiovanni P
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894727
[TBL] [Abstract][Full Text] [Related]
24. The PNPLA3 rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis.
Mederacke YS; Kirstein MM; Großhennig A; Marhenke S; Metzler F; Manns MP; Vogel A; Mederacke I
Aliment Pharmacol Ther; 2020 Jun; 51(11):1160-1168. PubMed ID: 32323349
[TBL] [Abstract][Full Text] [Related]
25. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.
Liu YL; Reeves HL; Burt AD; Tiniakos D; McPherson S; Leathart JB; Allison ME; Alexander GJ; Piguet AC; Anty R; Donaldson P; Aithal GP; Francque S; Van Gaal L; Clement K; Ratziu V; Dufour JF; Day CP; Daly AK; Anstee QM
Nat Commun; 2014 Jun; 5():4309. PubMed ID: 24978903
[TBL] [Abstract][Full Text] [Related]
26. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
[TBL] [Abstract][Full Text] [Related]
27. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
[TBL] [Abstract][Full Text] [Related]
28. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
[TBL] [Abstract][Full Text] [Related]
29. PNPLA3 I148M variant affects non-alcoholic fatty liver disease in liver transplant recipients.
Liu ZT; Chen TC; Lu XX; Cheng J; Xie HY; Zhou L; Zheng SS
World J Gastroenterol; 2015 Sep; 21(34):10054-6. PubMed ID: 26379412
[TBL] [Abstract][Full Text] [Related]
30. African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population.
Cavalcante LN; Porto J; Mazo D; Longatto-Filho A; Stefano JT; Lyra AC; Carrilho FJ; Reis RM; Alves VAF; Sanyal AJ; Oliveira CP
Ann Hepatol; 2022; 27(6):100728. PubMed ID: 35710086
[TBL] [Abstract][Full Text] [Related]
31. Correlations between PNPLA3 Gene Polymorphisms and NAFLD in Type 2 Diabetic Patients.
Gavril OI; Arhire LI; Gavril RS; Zota MI; Gherasim A; Nita O; Drugescu A; Oprescu AC; Esanu IM; Mitu F; Graur M; Mihalache L
Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833467
[No Abstract] [Full Text] [Related]
32. Associations between metabolic hyperferritinaemia, fibrosis-promoting alleles and clinical outcomes in steatotic liver disease.
Suresh D; Li A; Miller MJ; Wijarnpreecha K; Chen VL
Liver Int; 2024 Feb; 44(2):389-398. PubMed ID: 37971775
[TBL] [Abstract][Full Text] [Related]
33. Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype.
Tai J; Hsu CW; Chen WT; Yang SS; Chiu CH; Chien RN; Chang ML
Cancer Sci; 2024 Feb; 115(2):564-574. PubMed ID: 38083881
[TBL] [Abstract][Full Text] [Related]
34. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China.
Chen LZ; Ding HY; Liu SS; Liu Q; Jiang XJ; Xin YN; Xuan SY
Lipids Health Dis; 2019 Feb; 18(1):45. PubMed ID: 30738435
[TBL] [Abstract][Full Text] [Related]
35. Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease.
Grimaudo S; Pipitone RM; Pennisi G; Celsa C; Cammà C; Di Marco V; Barcellona MR; Boemi R; Enea M; Giannetti A; Spatola F; Marchesini G; Craxì A; Petta S
Clin Gastroenterol Hepatol; 2020 Apr; 18(4):935-944.e3. PubMed ID: 31419571
[TBL] [Abstract][Full Text] [Related]
36. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.
Akuta N; Kawamura Y; Arase Y; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Ikeda K; Kumada H
Gut Liver; 2016 May; 10(3):437-45. PubMed ID: 26610348
[TBL] [Abstract][Full Text] [Related]
37. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Gustot T; Deviere J; Debette S; Amouyel P; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Int J Cancer; 2019 Feb; 144(3):533-544. PubMed ID: 30289982
[TBL] [Abstract][Full Text] [Related]
38. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.
Seko Y; Yamaguchi K; Mizuno N; Okuda K; Takemura M; Taketani H; Hara T; Umemura A; Nishikawa T; Moriguchi M; Yasui K; Kamaguchi M; Nishioji K; Mochizuki N; Kobayashi M; Mori K; Tanaka S; Matsuura K; Tanaka Y; Itoh Y
J Gastroenterol; 2018 Mar; 53(3):438-448. PubMed ID: 28744823
[TBL] [Abstract][Full Text] [Related]
39. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
[TBL] [Abstract][Full Text] [Related]
40. The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: A multicentre cohort study.
Seko Y; Yamaguchi K; Shima T; Iwaki M; Takahashi H; Kawanaka M; Tanaka S; Mitsumoto Y; Yoneda M; Nakajima A; Fjellström O; Blau JE; Carlsson B; Okanoue T; Itoh Y
Liver Int; 2023 Oct; 43(10):2210-2219. PubMed ID: 37470077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
